New trial
Phase 2 linvoseltamab: BCMA and CD3 bispecific antibody
- Trial ID
- NCT07009899 on ClinicalTrials.gov
- Cancer type
- Multiple Myeloma
- Stage of research
- Exploratory
- Published in
- New in Oncology - July 3, 2025
This phase 2 study evaluates the safety and efficacy of linvoseltamab in multiple myeloma patients relapsed after BCMA CAR T-cell therapy. All subjects receive an initial inpatient step-up dosing regimen followed by weekly, biweekly, and monthly infusions in a single-center trial at the Medical College of Wisconsin in Milwaukee.
More in multiple myeloma
-
Trial result · Oct 22, 2026 · NCT04184050
MK-4002 (BCMA×CD3 trispecific T-cell engager) drives 63% ORR at 12 mg in heavily pretreated RRMM -
Trial result · Oct 15, 2026 · NCT04557150
Forimtamig (GPRC5D×CD3 2:1 bispecific) posts 72% ORR at optimized SC dosing—but toxicity caps escalation in RRMM -
New trial · Oct 15, 2026 · NCT06948084
Phase 2 daratumumab plus teclistamab is compared with DPd or DKd in high-risk, second-line multiple myeloma -
Trial result · Oct 1, 2026 · NCT03301220
Daratumumab (anti-CD38) cuts progression risk in Japanese high-risk SMM vs monitoring (AQUILA) -
Trial result · Sep 24, 2026 · NCT05469893
Teclistamab (BCMAxCD3 bispecific) drives 78% CR and 92% 2-year PFS in high-risk smoldering myeloma